{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T19:51:23Z","timestamp":1785268283412,"version":"3.55.0"},"reference-count":166,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T00:00:00Z","timestamp":1707696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell Dev. Biol."],"abstract":"<jats:p>Multiple myeloma (MM), a stage-developed plasma cell malignancy, evolves from monoclonal gammopathy of undetermined significance (MGUS) or smoldering MM (SMM). Emerging therapies including immunomodulatory drugs, proteasome inhibitors, monoclonal antibodies, chimeric antigen-T\/natural killer (NK) cells, bispecific T-cell engagers, selective inhibitors of nuclear export, and small-molecule targeted therapy have considerably improved patient survival. However, MM remains incurable owing to inevitable drug resistance and post-relapse rapid progression. NK cells with germline-encoded receptors are involved in the natural evolution of MGUS\/SMM to active MM. NK cells actively recognize aberrant plasma cells undergoing malignant transformation but are yet to proliferate during the elimination phase, a process that has not been revealed in the immune editing theory. They are potential effector cells that have been neglected in the therapeutic process. Herein, we characterized changes in NK cells regarding disease evolution and elucidated its role in the early clinical monitoring of MM. Additionally, we systematically explored dynamic changes in NK cells from treated patients who are in remission or relapse to explore future combination therapy strategies to overcome drug resistance.<\/jats:p>","DOI":"10.3389\/fcell.2024.1359084","type":"journal-article","created":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T04:46:27Z","timestamp":1707713187000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Natural killer cells affect the natural course, drug resistance, and prognosis of multiple myeloma"],"prefix":"10.3389","volume":"12","author":[{"given":"Li","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohuan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liansheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,2,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1002\/cyto.a.23693","article-title":"High-parameter mass cytometry evaluation of relapsed\/refractory multiple myeloma patients treated with daratumumab demonstrates immune modulation as a novel mechanism of action","volume":"95","author":"Adams","year":"2019","journal-title":"Cytom. A"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","article-title":"T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1182\/blood-2019-126146","article-title":"Multidimensional single cell analysis shows increased T\/Nk cell subsets in both blood and bone marrow of iberdomide (Cc-220) treated relapsed\/refractory multiple myeloma patients","volume":"134","author":"Amatangelo","year":"2019","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1038\/bmt.2017.29","article-title":"Multiple myeloma patients in long-term complete response after autologous stem cell transplantation express a particular immune signature with potential prognostic implication","volume":"52","author":"Arteche-L\u00f3pez","year":"2017","journal-title":"Bone Marrow Transpl."},{"key":"B6","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.pharmthera.2019.06.004","article-title":"Molecular mechanisms of cereblon-based drugs","volume":"202","author":"Asatsuma-Okumura","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e1486356","DOI":"10.1080\/2162402x.2018.1486356","article-title":"The prognostic and predictive value of Ikzf1 and Ikzf3 expression in T-cells in patients with multiple myeloma","volume":"7","author":"Awwad","year":"2018","journal-title":"Oncoimmunology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e002866","DOI":"10.1136\/jitc-2021-002866","article-title":"Nk cells enhance car-T cell antitumor efficacy by enhancing immune\/tumor cells cluster formation and improving car-T cell fitness","volume":"9","author":"Bachiller","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e582","DOI":"10.1097\/hs9.0000000000000582","article-title":"Biology of germinal center B cells relating to lymphomagenesis","volume":"5","author":"Basso","year":"2021","journal-title":"Hemasphere"},{"key":"B10","doi-asserted-by":"publisher","first-page":"6387","DOI":"10.1182\/blood-2011-06-360255","article-title":"Iph2101, a novel anti-inhibitory kir antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect","volume":"118","author":"Benson","year":"2011","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/j.humimm.2009.07.004","article-title":"Changes in activatory and inhibitory natural killer (Nk) receptors may induce progression to multiple myeloma: implications for tumor evasion of T and Nk cells","volume":"70","author":"Bernal","year":"2009","journal-title":"Hum. Immunol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"7407","DOI":"10.1182\/blood-2022-160203","article-title":"Knock-in of the Bcl2 G101v mutation in human ipsc-derived Nk cells generates venetoclax resistance and improves activity against venetoclax resistant aml","volume":"140","author":"Bernareggi","year":"2022","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","first-page":"704","DOI":"10.3389\/fimmu.2018.00704","article-title":"One-year follow-up of natural killer cell activity in multiple myeloma patients treated with adjuvant lenalidomide therapy","volume":"9","author":"Besson","year":"2018","journal-title":"Front. Immunol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2081415","DOI":"10.1080\/2162402x.2022.2081415","article-title":"Crispr-Cas9 based gene editing of the immune checkpoint Nkg2a enhances Nk cell mediated cytotoxicity against multiple myeloma","volume":"11","author":"Bexte","year":"2022","journal-title":"Oncoimmunology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.bbmt.2018.11.015","article-title":"Peripheral immunotype correlates with minimal residual disease status and is modulated by immunomodulatory drugs in multiple myeloma","volume":"25","author":"Bhutani","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"B16","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1182\/bloodadvances.2020002440","article-title":"Fc\u03b5ri\u03b3-negative Nk cells persist in vivo and enhance efficacy of therapeutic monoclonal antibodies in multiple myeloma","volume":"5","author":"Bigley","year":"2021","journal-title":"Blood Adv."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1182\/blood-2021-153994","article-title":"Pre-clinical and clinical immunomodulatory effects of pomalidomide or cc-92480 in combination with bortezomib in multiple myeloma","volume":"138","author":"Bjorklund","year":"2021","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1016\/j.ymthe.2018.06.012","article-title":"Car T cells with enhanced sensitivity to B cell maturation antigen for the targeting of B cell non-hodgkin's lymphoma and multiple myeloma","volume":"26","author":"Bluhm","year":"2018","journal-title":"Mol. Ther."},{"key":"B19","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1186\/s40425-019-0751-5","article-title":"Targeting of Cxcr3 improves anti-myeloma efficacy of adoptively transferred activated natural killer cells","volume":"7","author":"Bonanni","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1200\/jco.2018.77.8084","article-title":"T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma","volume":"36","author":"Brudno","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.coi.2017.02.001","article-title":"Stimulating Cd27 to quantitatively and qualitatively shape adaptive immunity to cancer","volume":"45","author":"Bullock","year":"2017","journal-title":"Curr. Opin. Immunol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.3389\/fimmu.2018.02551","article-title":"Mechanisms of Nk cell activation and clinical activity of the therapeutic Slamf7 antibody, elotuzumab in multiple myeloma","volume":"9","author":"Campbell","year":"2018","journal-title":"Front. Immunol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e1534664","DOI":"10.1080\/2162402x.2018.1534664","article-title":"Bortezomib sensitizes multiple myeloma to Nk cells via Er-Stress-Induced suppression of hla-E and upregulation of Dr5","volume":"8","author":"Carlsten","year":"2019","journal-title":"Oncoimmunology"},{"key":"B24","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/s41375-020-0855-4","article-title":"Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab","volume":"35","author":"Casneuf","year":"2021","journal-title":"Leukemia"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1182\/bloodadvances.2017006866","article-title":"Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma","volume":"1","author":"Casneuf","year":"2017","journal-title":"Blood Adv."},{"key":"B26","doi-asserted-by":"publisher","first-page":"3613","DOI":"10.3390\/ijms19113613","article-title":"Immunotherapy: a novel era of promising treatments for multiple myeloma","volume":"19","author":"Castella","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1158\/2326-6066.Cir-17-0649","article-title":"A Cs1-Nkg2d bispecific antibody collectively activates cytolytic immune cells against multiple myeloma","volume":"6","author":"Chan","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/s41423-019-0222-4","article-title":"Nk cell recognition of hematopoietic cells by slam-sap families","volume":"16","author":"Chen","year":"2019","journal-title":"Cell Mol. Immunol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"103799","DOI":"10.1016\/j.jri.2023.103799","article-title":"Immune checkpoint inhibitors and reproductive failures","volume":"156","author":"Chen","year":"2023","journal-title":"J. Reprod. Immunol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.1158\/1078-0432.Ccr-20-3418","article-title":"Adaptive natural killer cells facilitate effector functions of daratumumab in multiple myeloma","volume":"27","author":"Cho","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.1182\/blood-2019-124490","article-title":"Nk cells lacking Cd38 are resistant to oxidative stress-induced death","volume":"134","author":"Cichocki","year":"2019","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/ni.1693","article-title":"Influence of cracc, a slam family receptor coupled to the adaptor eat-2, on natural killer cell function","volume":"10","author":"Cruz-Munoz","year":"2009","journal-title":"Nat. Immunol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1182\/bloodadvances.2021006805","article-title":"Targeting hypersialylation in multiple myeloma represents a novel approach to enhance Nk cell-mediated tumor responses","volume":"6","author":"Daly","year":"","journal-title":"Blood Adv."},{"key":"B34","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1182\/bloodadvances.2021006805","article-title":"Targeting hypersialylation in multiple myeloma represents a novel approach to enhance Nk cell\u2013mediated tumor responses","volume":"6","author":"Daly","year":"","journal-title":"Blood Adv."},{"key":"B35","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s00432-018-2807-1","article-title":"Clinical and biological characteristics of myeloma patients influence response to elotuzumab combination therapy","volume":"145","author":"Danhof","year":"2019","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41591-021-01245-5","article-title":"Homozygous bcma gene deletion in response to anti-bcma car T cells in a patient with multiple myeloma","volume":"27","author":"Da Vi\u00e0","year":"2021","journal-title":"Nat. Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1182\/blood-2016-09-692954","article-title":"Mgus to myeloma: a mysterious gammopathy of underexplored significance","volume":"128","author":"Dhodapkar","year":"2016","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","first-page":"4972","DOI":"10.1158\/1538-7445.Am2019-4972","article-title":"Abstract 4972: preclinical development of a first-in-class Nkp30xbcma Nk cell engager for the treatment of multiple myeloma","volume":"79","author":"Draghi","year":"2019","journal-title":"Cancer Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1158\/2326-6066.Cir-17-0279","article-title":"Il15 infusion of cancer patients expands the subpopulation of cytotoxic Cd56(bright) Nk cells and increases Nk-cell cytokine release capabilities","volume":"5","author":"Dubois","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"B41","doi-asserted-by":"crossref","DOI":"10.1101\/2022.08.22.504722","article-title":"Single-cell functional genomics of natural killer cell evasion in blood cancers","author":"Dufva","year":"2022"},{"key":"B42","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1016\/j.molimm.2010.05.003","article-title":"The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (trail) expression and natural killer (Nk) cell killing of trail receptor-positive multiple myeloma cells","volume":"47","author":"Feng","year":"2010","journal-title":"Mol. Immunol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.clml.2022.07.001","article-title":"High dimensional immune profiling of smoldering multiple myeloma distinguishes distinct tumor microenvironments","volume":"22","author":"Fernandez","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"B44","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1182\/bloodadvances.2022007985","article-title":"Improving Nk cell function in multiple myeloma with Nktr-255, a novel polymer-conjugated human il-15","volume":"7","author":"Fernandez","year":"2023","journal-title":"Blood Adv."},{"key":"B45","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1182\/blood-2013-02-482513","article-title":"Downregulation of the activating Nkp30 ligand B7-H6 by hdac inhibitors impairs tumor cell recognition by Nk cells","volume":"122","author":"Fiegler","year":"2013","journal-title":"Blood"},{"key":"B46","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.ctrv.2018.10.005","article-title":"Translating the anti-myeloma activity of natural killer cells into clinical application","volume":"70","author":"Fionda","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"B47","doi-asserted-by":"publisher","first-page":"785635","DOI":"10.3389\/fonc.2021.785635","article-title":"Selinexor enhances Nk cell activation against malignant B cells via downregulation of hla-E","volume":"11","author":"Fisher","year":"2021","journal-title":"Front. Oncol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13045-015-0134-4","article-title":"Tim-3\/Gal-9 interaction induces ifn\u03b3-dependent Ido1 expression in acute myeloid leukemia blast cells","volume":"8","author":"Folgiero","year":"2015","journal-title":"J. Hematol. Oncol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1182\/blood-2021-152505","article-title":"Central memory T-cell differentiation correlates with depth of response in relapsed\/refractory multiple myeloma patients receiving elotuzumab in combination with carfilzomib, lenalidomide and dexamethasone (Elo-Krd)","volume":"138","author":"Foureau","year":"2021","journal-title":"Blood"},{"key":"B50","doi-asserted-by":"publisher","first-page":"e946365","DOI":"10.4161\/21624011.2014.946365","article-title":"Reversal of natural killer cell exhaustion by tim-3 blockade","volume":"3","author":"Gallois","year":"2014","journal-title":"Oncoimmunology"},{"key":"B51","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1111\/bjh.12708","article-title":"Immunomodulatory agents lenalidomide and pomalidomide Co-stimulate T cells by inducing degradation of T cell repressors ikaros and aiolos via modulation of the E3 ubiquitin ligase complex crl4(crbn.)","volume":"164","author":"Gandhi","year":"2014","journal-title":"Br. J. Haematol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to Cd38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"key":"B53","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1182\/bloodadvances.2019000600","article-title":"T-cell phenotypes associated with effective car T-cell therapy in postinduction vs relapsed multiple myeloma","volume":"3","author":"Garfall","year":"2019","journal-title":"Blood Adv."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1084\/jem.20051511","article-title":"Cd4+Cd25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner","volume":"202","author":"Ghiringhelli","year":"2005","journal-title":"J. Exp. Med."},{"key":"B55","doi-asserted-by":"publisher","first-page":"24031","DOI":"10.18632\/oncotarget.15234","article-title":"Activation of Nk cells and disruption of Pd-L1\/Pd-1 Axis: two different ways for lenalidomide to block myeloma progression","volume":"8","author":"Giuliani","year":"2017","journal-title":"Oncotarget"},{"key":"B56","doi-asserted-by":"publisher","first-page":"Itc177","DOI":"10.7326\/aitc202212200","article-title":"Monoclonal gammopathy of undetermined significance","volume":"175","author":"Gonsalves","year":"2022","journal-title":"Ann. Intern Med."},{"key":"B57","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1182\/blood-2020-142750","article-title":"Ft576: multi-specific off-the-shelf car-Nk cell therapy engineered for enhanced persistence, avoidance of self-fratricide and optimized mab combination therapy to prevent antigenic escape and elicit a deep and durable response in multiple myeloma","volume":"136","author":"Goodridge","year":"2020","journal-title":"Blood"},{"key":"B58","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1182\/blood-2010-04-279893","article-title":"Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma","volume":"116","author":"G\u00f6rg\u00fcn","year":"2010","journal-title":"Blood"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1182\/blood-2018-01-825265","article-title":"Tigit immune checkpoint blockade restores Cd8(+) T-cell immunity against multiple myeloma","volume":"132","author":"Guillerey","year":"2018","journal-title":"Blood"},{"key":"B60","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3390\/cells9020321","article-title":"Targeting Cd38-expressing multiple myeloma and burkitt lymphoma cells in vitro with nanobody-based chimeric antigen receptors (Nb-cars)","volume":"9","author":"Hambach","year":"2020","journal-title":"Cells"},{"key":"B61","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/j.1365-2141.2004.05286.x","article-title":"Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application","volume":"128","author":"Hayashi","year":"2005","journal-title":"Br. J. Haematol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/s41375-020-0809-x","article-title":"Immunomodulatory drugs activate Nk cells via both zap-70 and cereblon-dependent pathways","volume":"35","author":"Hideshima","year":"2021","journal-title":"Leukemia"},{"key":"B63","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13046-021-01909-7","article-title":"Small-molecule hdac and Akt inhibitors suppress tumor growth and enhance immunotherapy in multiple myeloma","volume":"40","author":"Hirano","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"B64","doi-asserted-by":"publisher","first-page":"8065","DOI":"10.1200\/JCO.2022.40.16_suppl.8065","article-title":"Immune cell differences between patients in different stages of monoclonal plasma cell disorders","volume":"40","author":"Ho","year":"","journal-title":"J. Clin. Oncol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"8975","DOI":"10.3390\/curroncol29110705","article-title":"Treating multiple myeloma in the context of the bone marrow microenvironment","volume":"29","author":"Ho","year":"","journal-title":"Curr. Oncol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"4451","DOI":"10.1182\/blood-2019-128467","article-title":"Results of a phase I study of pnk-007, allogeneic, off the shelf Nk cell, post autologous transplant in multiple myeloma (Nct02955550)","volume":"134","author":"Holstein","year":"2019","journal-title":"Blood"},{"key":"B67","doi-asserted-by":"publisher","first-page":"4416","DOI":"10.1200\/jco.23.00512","article-title":"Chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma: moving into the future","volume":"41","author":"Holstein","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1080\/10428194.2019.1688324","article-title":"Optimal sequence of daratumumab and elotuzumab in relapsed and refractory multiple myeloma","volume":"61","author":"Hoylman","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"B69","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1158\/1078-0432.Ccr-07-4246","article-title":"Cs1, a potential new therapeutic antibody target for the treatment of multiple myeloma","volume":"14","author":"Hsi","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"B70","doi-asserted-by":"publisher","first-page":"108722","DOI":"10.1016\/j.intimp.2022.108722","article-title":"Drug resistance biomarker Abcc4 of selinexor and immune feature in multiple myeloma","volume":"108","author":"Hu","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13045-023-01435-3","article-title":"Car-Nk cell therapy for hematological malignancies: recent updates from ash 2022","volume":"16","author":"Huang","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"792609","DOI":"10.3389\/fimmu.2021.792609","article-title":"Gene expression analysis of the bone marrow microenvironment reveals distinct immunotypes in smoldering multiple myeloma associated to progression to symptomatic disease","volume":"12","author":"Isola","year":"2021","journal-title":"Front. Immunol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"583","DOI":"10.3389\/fimmu.2015.00583","article-title":"Nk cell subgroups, phenotype, and functions after autologous stem cell transplantation","volume":"6","author":"Jacobs","year":"2015","journal-title":"Front. Immunol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"5250","DOI":"10.1182\/blood-2018-99-113578","article-title":"Tigit expression positively associates with Nk cell function in aml patients","volume":"132","author":"Jia","year":"2018","journal-title":"Blood"},{"key":"B75","doi-asserted-by":"publisher","first-page":"119","DOI":"10.22034\/iji.2021.87547.1812","article-title":"Effect of bortezomib regimens and daratumumab monotherapy on cellular immunity in multiple myeloma patients","volume":"18","author":"Kakoo","year":"2021","journal-title":"Iran. J. Immunol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"101544","DOI":"10.1016\/j.trim.2022.101544","article-title":"Prognostic impact of natural killer cell recovery on minimal residual disease after autologous stem cell transplantation in multiple myeloma","volume":"71","author":"Keruakous","year":"2022","journal-title":"Transpl. Immunol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1080\/17474086.2019.1617128","article-title":"Potential of Nk cells in multiple myeloma therapy","volume":"12","author":"Khan","year":"2019","journal-title":"Expert Rev. Hematol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.exphem.2022.03.012","article-title":"Prognostic role of the ratio of natural killer cells to regulatory T cells in patients with multiple myeloma treated with lenalidomide and dexamethasone","volume":"110","author":"Kim","year":"2022","journal-title":"Exp. Hematol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"e0150434","DOI":"10.1371\/journal.pone.0150434","article-title":"Cd45 isoform profile identifies natural killer (Nk) subsets with differential activity","volume":"11","author":"Krzywinska","year":"2016","journal-title":"PLoS One"},{"key":"B80","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.3389\/fimmu.2019.03010","article-title":"Recalling the biological significance of immune checkpoints on Nk cells: a chance to overcome Lag3, Pd1, and Ctla4 inhibitory pathways by adoptive Nk cell transfer?","volume":"10","author":"Lanuza","year":"2019","journal-title":"Front. Immunol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1182\/blood-2003-02-0361","article-title":"Immunomodulatory drug costimulates T cells via the B7-Cd28 pathway","volume":"103","author":"LeBlanc","year":"2004","journal-title":"Blood"},{"key":"B82","doi-asserted-by":"publisher","first-page":"e1250051","DOI":"10.1080\/2162402x.2016.1250051","article-title":"Novel treatment strategy with autologous activated and expanded natural killer cells plus anti-myeloma drugs for multiple myeloma","volume":"5","author":"Leivas","year":"2016","journal-title":"Oncoimmunology"},{"key":"B83","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1182\/blood-2018-99-114522","article-title":"Nkg2d-Car transduced primary natural killer cells efficiently target multiple myeloma cells","volume":"132","author":"Leivas","year":"2018","journal-title":"Blood"},{"key":"B84","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/s41408-021-00537-w","article-title":"Nkg2d-Car-Transduced natural killer cells efficiently target multiple myeloma","volume":"11","author":"Leivas","year":"2021","journal-title":"Blood Cancer J."},{"key":"B85","doi-asserted-by":"publisher","first-page":"114526","DOI":"10.1016\/j.bcp.2021.114526","article-title":"Susceptibility of multiple myeloma to B-cell lymphoma 2 family inhibitors","volume":"188","author":"Lernoux","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"977","DOI":"10.3389\/fimmu.2018.00977","article-title":"Immunomodulatory drugs exert anti-leukemia effects in acute myeloid leukemia by direct and immunostimulatory activities","volume":"9","author":"Le Roy","year":"2018","journal-title":"Front. Immunol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"8603","DOI":"10.3390\/ijms24108603","article-title":"Study on the effect of Ezh2 inhibitor combined with tigit monoclonal antibody against multiple myeloma cells","volume":"24","author":"Liu","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B88","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s00262-018-2140-1","article-title":"Daratumumab augments alloreactive natural killer cell cytotoxicity towards Cd38+ multiple myeloma cell lines in a biochemical context mimicking tumour microenvironment conditions","volume":"67","author":"Mahaweni","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"key":"B89","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1084\/jem.20050128","article-title":"Il-18-Induced Cd83+Ccr7+ Nk helper cells","volume":"202","author":"Mailliard","year":"2005","journal-title":"J. Exp. Med."},{"key":"B90","first-page":"1637","article-title":"Cs1 (Slamf7, Cd319) is an effective immunotherapeutic target for multiple myeloma","volume":"7","author":"Malaer","year":"2017","journal-title":"Am. J. Cancer Res."},{"key":"B91","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1097\/01.Hs9.0000563120.66927.63","article-title":"Ps1209 Nkg2d and bcma-car Nk cells efficiently eliminate multiple myeloma cells. A comprehensive comparison between two clinically relevant cars","volume":"3","author":"Maroto-Mart\u00edn","year":"2019","journal-title":"HemaSphere"},{"key":"B92","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1158\/1078-0432.Ccr-20-1395","article-title":"Designing evolutionary-based interception strategies to block the transition from precursor phases to multiple myeloma","volume":"27","author":"Maura","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"B93","doi-asserted-by":"publisher","first-page":"440","DOI":"10.3390\/cancers12020440","article-title":"Bone marrow stromal cell-derived il-8 upregulates pvr expression on multiple myeloma cells via nf-kb transcription factor","volume":"12","author":"Mekhloufi","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B94","doi-asserted-by":"publisher","first-page":"310.e1","DOI":"10.1016\/j.jtct.2020.10.023","article-title":"Early adaptive natural killer cell expansion is associated with decreased relapse after autologous transplantation for multiple myeloma","volume":"27","author":"Merino","year":"2021","journal-title":"Transpl. Cell Ther."},{"key":"B95","doi-asserted-by":"publisher","first-page":"967","DOI":"10.3390\/cells10050967","article-title":"Selection, expansion, and unique pretreatment of allogeneic human natural killer cells with anti-Cd38 monoclonal antibody for efficient multiple myeloma treatment","volume":"10","author":"Motais","year":"2021","journal-title":"Cells"},{"key":"B96","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1182\/blood.2020006200","article-title":"Cd38 deletion of human primary Nk cells eliminates daratumumab-induced fratricide and boosts their effector activity","volume":"136","author":"Naeimi Kararoudi","year":"2020","journal-title":"Blood, J. Am. Soc. Hematol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1182\/blood-2019-129456","article-title":"Cd38 knockout primary Nk cells to prevent \"fratricide\" and boost daratumumab activity","volume":"134","author":"Nagai","year":"2019","journal-title":"Blood"},{"key":"B98","doi-asserted-by":"publisher","first-page":"e0211927","DOI":"10.1371\/journal.pone.0211927","article-title":"Infectious complications and Nk cell depletion following daratumumab treatment of multiple myeloma","volume":"14","author":"Nahi","year":"2019","journal-title":"PLoS One"},{"key":"B99","doi-asserted-by":"publisher","first-page":"100508","DOI":"10.1016\/j.xcrm.2022.100508","article-title":"Autologous Nk cells as consolidation therapy following stem cell transplantation in multiple myeloma","volume":"3","author":"Nahi","year":"2022","journal-title":"Cell Rep. Med."},{"key":"B100","doi-asserted-by":"publisher","first-page":"10761","DOI":"10.3390\/ijms221910761","article-title":"Synergistic effects of venetoclax and daratumumab on antibody-dependent cell-mediated natural killer cytotoxicity in multiple myeloma","volume":"22","author":"Nakamura","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B101","first-page":"2020","article-title":"Lag3 is a central regulator of Nk cell cytokine production","author":"Narayanan","year":"2022"},{"key":"B102","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1016\/j.cell.2022.04.006","article-title":"Advancing natural killer therapies against cancer","volume":"185","author":"Narni-Mancinelli","year":"2022","journal-title":"Cell"},{"key":"B103","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41417-021-00365-x","article-title":"Cxcr4 and anti-bcma car Co-modified natural killer cells suppress multiple myeloma progression in a xenograft mouse model","volume":"29","author":"Ng","year":"2022","journal-title":"Cancer Gene Ther."},{"key":"B104","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1097\/cji.0000000000000097","article-title":"Lenalidomide synergistically enhances the effect of dendritic cell vaccination in a model of murine multiple myeloma","volume":"38","author":"Nguyen-Pham","year":"2015","journal-title":"J. Immunother."},{"key":"B105","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1038\/leu.2015.123","article-title":"Upregulation of Cd38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab","volume":"29","author":"Nijhof","year":"2015","journal-title":"Leukemia"},{"key":"B106","doi-asserted-by":"publisher","first-page":"5954","DOI":"10.18632\/oncotarget.13979","article-title":"Low-dose bortezomib increases the expression of Nkg2d and dnam-1 ligands and enhances induced Nk and \u03b3\u03b4 T cell-mediated lysis in multiple myeloma","volume":"8","author":"Niu","year":"2017","journal-title":"Oncotarget"},{"key":"B107","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/j.febslet.2007.02.045","article-title":"Histone deacetylase inhibitors suppress natural killer cell cytolytic activity","volume":"581","author":"Ogbomo","year":"2007","journal-title":"FEBS Lett."},{"key":"B108","doi-asserted-by":"publisher","first-page":"748207","DOI":"10.3389\/fimmu.2021.748207","article-title":"Nk cell reconstitution after autologous hematopoietic stem cell transplantation: association between Nk cell maturation stage and outcome in multiple myeloma","volume":"12","author":"Orrantia","year":"2021","journal-title":"Front. Immunol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"105235","DOI":"10.1016\/j.isci.2022.105235","article-title":"In vivo expansion of a Cd9(+) decidual-like Nk cell subset following autologous hematopoietic stem cell transplantation","volume":"25","author":"Orrantia","year":"2022","journal-title":"iScience"},{"key":"B110","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1182\/blood-2015-10-662320","article-title":"Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under lendex: a longitudinal analysis","volume":"127","author":"Paiva","year":"2016","journal-title":"Blood"},{"key":"B111","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/j.cell.2022.03.030","article-title":"Augmenting Nk cell-based immunotherapy by targeting mitochondrial apoptosis","volume":"185","author":"Pan","year":"2022","journal-title":"Cell"},{"key":"B112","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3322\/caac.21771","article-title":"Chimeric antigen receptor T-cell therapy in multiple myeloma: a comprehensive review of current data and implications for clinical practice","volume":"73","author":"Parikh","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"B113","doi-asserted-by":"publisher","first-page":"3330","DOI":"10.3390\/cancers14143330","article-title":"Updates in the use of bcl-2-family small molecule inhibitors for the treatment of relapsed\/refractory multiple myeloma","volume":"14","author":"Parrondo","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B114","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.3390\/biomedicines10102450","article-title":"Nf-\u03bab mutations in germinal center B-cell lymphomas: relation to nf-\u03bab function in normal B cells","volume":"10","author":"Pasqualucci","year":"2022","journal-title":"Biomedicines"},{"key":"B115","doi-asserted-by":"publisher","first-page":"e1339853","DOI":"10.1080\/2162402x.2017.1339853","article-title":"The anti-slamf7 antibody elotuzumab mediates Nk cell activation through both Cd16-dependent and -independent mechanisms","volume":"6","author":"Pazina","year":"2017","journal-title":"Oncoimmunology"},{"key":"B116","doi-asserted-by":"publisher","first-page":"4766","DOI":"10.1158\/0008-5472.Can-15-1320","article-title":"Multiple myeloma impairs bone marrow localization of effector natural killer cells by altering the chemokine microenvironment","volume":"75","author":"Ponzetta","year":"2015","journal-title":"Cancer Res."},{"key":"B117","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1002\/jlb.Mr0718-269r","article-title":"Mechanisms of natural killer cell-mediated cellular cytotoxicity","volume":"105","author":"Prager","year":"2019","journal-title":"J. Leukoc. Biol."},{"key":"B118","doi-asserted-by":"publisher","first-page":"1853314","DOI":"10.1080\/2162402x.2020.1853314","article-title":"Expanded Nk cells from umbilical cord blood and adult peripheral blood combined with daratumumab are effective against tumor cells from multiple myeloma patients","volume":"10","author":"Reina-Ortiz","year":"2020","journal-title":"Oncoimmunology"},{"key":"B119","doi-asserted-by":"publisher","first-page":"4560","DOI":"10.1182\/blood-2022-170501","article-title":"Ft555: off-the-shelf car-Nk cell therapy Co-targeting Gprc5d and Cd38 for the treatment of multiple myeloma","volume":"140","author":"Reiser","year":"2022","journal-title":"Blood"},{"key":"B120","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3324\/haematol.2021.279930","article-title":"The efficacy of combination treatment with elotuzumab and lenalidomide is dependent on crosstalk between natural killer cells, monocytes and myeloma cells","volume":"108","author":"Richardson","year":"2023","journal-title":"Haematologica"},{"key":"B121","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41419-020-02867-2","article-title":"Venetoclax causes metabolic reprogramming independent of bcl-2 inhibition","volume":"11","author":"Roca-Portoles","year":"2020","journal-title":"Cell Death Dis."},{"key":"B122","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1182\/blood-2018-99-118970","article-title":"Preclinical characterization of Afm26, a novel B cell maturation antigen (Bcma)-Directed tetravalent bispecific antibody for high affinity retargeting of Nk cells against myeloma","volume":"132","author":"Ross","year":"2018","journal-title":"Blood"},{"key":"B123","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1189\/jlb.0711339","article-title":"Histone deacetylase inhibitors impair Nk cell viability and effector functions through inhibition of activation and receptor expression","volume":"91","author":"Rossi","year":"2012","journal-title":"J. Leukoc. Biol."},{"key":"B124","doi-asserted-by":"publisher","first-page":"e0218674","DOI":"10.1371\/journal.pone.0218674","article-title":"Tumor- and cytokine-primed human natural killer cells exhibit distinct phenotypic and transcriptional signatures","volume":"14","author":"Sabry","year":"2019","journal-title":"PLoS One"},{"key":"B125","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","article-title":"Biallelic loss of bcma as a resistance mechanism to car T cell therapy in a patient with multiple myeloma","volume":"12","author":"Samur","year":"2021","journal-title":"Nat. Commun."},{"key":"B126","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s00262-019-02477-8","article-title":"The Cd38(low) natural killer cell line Khyg1 transiently expressing Cd16(F158v) in combination with daratumumab targets multiple myeloma cells with minimal effector Nk cell fratricide","volume":"69","author":"Sarkar","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"key":"B127","doi-asserted-by":"publisher","first-page":"e64835","DOI":"10.1371\/journal.pone.0064835","article-title":"Hypoxia induced impairment of Nk cell cytotoxicity against multiple myeloma can Be overcome by il-2 activation of the Nk cells","volume":"8","author":"Sarkar","year":"2013","journal-title":"PLoS One"},{"key":"B128","doi-asserted-by":"publisher","first-page":"69408","DOI":"10.18632\/oncotarget.11242","article-title":"Serum protein fingerprinting by pea immunoassay coupled with a pattern-recognition algorithms distinguishes mgus and multiple myeloma","volume":"8","author":"Schneiderova","year":"2017","journal-title":"Oncotarget"},{"key":"B129","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/s41586-023-05912-0","article-title":"The Nk cell receptor Nkp46 recognizes ecto-calreticulin on Er-stressed cells","volume":"616","author":"Sen Santara","year":"2023","journal-title":"Nature"},{"key":"B130","doi-asserted-by":"publisher","first-page":"5152","DOI":"10.1182\/bloodadvances.2022007905","article-title":"Nk cells Cd56bright and Cd56dim subset cytokine loss and exhaustion is associated with impaired survival in myeloma","volume":"6","author":"Seymour","year":"2022","journal-title":"Blood Adv."},{"key":"B131","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1158\/1078-0432.Ccr-21-3803","article-title":"Fda approval summary: idecabtagene vicleucel for relapsed or refractory multiple myeloma","volume":"28","author":"Sharma","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"B132","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1182\/blood-2007-03-078535","article-title":"Bortezomib down-regulates the cell-surface expression of hla class I and enhances natural killer cell-mediated lysis of myeloma","volume":"111","author":"Shi","year":"2008","journal-title":"Blood"},{"key":"B133","doi-asserted-by":"publisher","first-page":"42370","DOI":"10.1021\/acsami.1c08986","article-title":"Bispecific antibody designed for targeted Nk cell activation and functional assessment for biomedical applications","volume":"13","author":"Song","year":"2021","journal-title":"ACS Appl. Mater Interfaces"},{"key":"B134","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1182\/blood-2008-08-173914","article-title":"Atm-atr-dependent up-regulation of dnam-1 and Nkg2d ligands on multiple myeloma cells by therapeutic agents results in enhanced Nk-cell susceptibility and is associated with a senescent phenotype","volume":"113","author":"Soriani","year":"2009","journal-title":"Blood"},{"key":"B135","doi-asserted-by":"publisher","first-page":"8009","DOI":"10.1200\/JCO.2022.40.16_suppl.8009","article-title":"Phase ii study of umbilical cord blood\u2013derived natural killer (Cb-Nk) cells with elotuzumab, lenalidomide, and high-dose melphalan followed by autologous stem cell transplantation (asct) for patients with high-risk multiple myeloma (hrmm)","volume":"40","author":"Srour","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"B136","doi-asserted-by":"publisher","first-page":"e596","DOI":"10.1097\/hs9.0000000000000596","article-title":"Cd38-Specific chimeric antigen receptor expressing natural killer khyg-1 cells: a proof of concept for an \"off the shelf\" therapy for multiple myeloma","volume":"5","author":"Stikvoort","year":"2021","journal-title":"Hemasphere"},{"key":"B137","doi-asserted-by":"publisher","first-page":"e002958","DOI":"10.1136\/jitc-2021-002958","article-title":"Individualized genetic makeup that controls natural killer cell function influences the efficacy of isatuximab immunotherapy in patients with multiple myeloma","volume":"9","author":"Sun","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"B138","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA a cancer J. Clin."},{"key":"B139","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1007\/s00262-022-03317-y","article-title":"Generation of Nk cells with chimeric-switch receptors to overcome Pd1-mediated inhibition in cancer immunotherapy","volume":"72","author":"Susek","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"B140","doi-asserted-by":"publisher","first-page":"11712","DOI":"10.1158\/0008-5472.Can-05-1657","article-title":"Immunomodulatory drug lenalidomide (Cc-5013, Imid3) augments anti-Cd40 sgn-40-induced cytotoxicity in human multiple myeloma: clinical implications","volume":"65","author":"Tai","year":"2005","journal-title":"Cancer Res."},{"key":"B141","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1038\/s41423-021-00686-9","article-title":"Expanded natural killer cells augment the antimyeloma effect of daratumumab, bortezomib, and dexamethasone in a mouse model","volume":"18","author":"Thangaraj","year":"2021","journal-title":"Cell Mol. Immunol."},{"key":"B142","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.3389\/fimmu.2018.02743","article-title":"Enhancing the activation and releasing the brakes: a double hit strategy to improve Nk cell cytotoxicity against multiple myeloma","volume":"9","author":"Tognarelli","year":"2018","journal-title":"Front. Immunol."},{"key":"B143","doi-asserted-by":"publisher","first-page":"100968","DOI":"10.1016\/j.mam.2021.100968","article-title":"Nk cell surveillance of hematological malignancies. Therapeutic implications and regulation by chemokine receptors","volume":"80","author":"Tomaipitinca","year":"2021","journal-title":"Mol. Asp. Med."},{"key":"B144","doi-asserted-by":"publisher","first-page":"e09167","DOI":"10.1016\/j.heliyon.2022.e09167","article-title":"Natural killer cells activity against multiple myeloma cells is modulated by osteoblast-induced il-6 and il-10 production","volume":"8","author":"Uhl","year":"2022","journal-title":"Heliyon"},{"key":"B145","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s00277-020-04303-z","article-title":"Haploidentical transplantation in patients with multiple myeloma making use of natural killer cell alloreactive donors","volume":"100","author":"Van Elssen","year":"2021","journal-title":"Ann. Hematol."},{"key":"B146","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1158\/1078-0432.Ccr-13-2302","article-title":"Natural killer cells: the secret weapon in dendritic cell vaccination strategies","volume":"20","author":"Van Elssen","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"B147","doi-asserted-by":"publisher","first-page":"904","DOI":"10.3390\/ijms23020904","article-title":"Dendritic cell-based immunotherapy in multiple myeloma: challenges, opportunities, and future directions","volume":"23","author":"Verheye","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B148","doi-asserted-by":"publisher","first-page":"e881","DOI":"10.1097\/hs9.0000000000000881","article-title":"Nk cell phenotype is associated with response and resistance to daratumumab in relapsed\/refractory multiple myeloma","volume":"7","author":"Verkleij","year":"2023","journal-title":"Hemasphere"},{"key":"B149","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/s41375-020-0810-4","article-title":"Daratumumab induces mechanisms of immune activation through Cd38+ Nk cell targeting","volume":"35","author":"Viola","year":"2021","journal-title":"Leukemia"},{"key":"B150","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1182\/blood-2005-05-2177","article-title":"A novel bispecific protein (Ulbp2-Bb4) targeting the Nkg2d receptor on natural killer (Nk) cells and Cd138 activates Nk cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo","volume":"107","author":"von Strandmann","year":"2006","journal-title":"Blood"},{"key":"B151","doi-asserted-by":"publisher","first-page":"e12176","DOI":"10.1002\/jev2.12176","article-title":"Impact on Nk cell functions of acute versus chronic exposure to extracellular vesicle-associated mica: dual role in cancer immunosurveillance","volume":"11","author":"Vulpis","year":"2022","journal-title":"J. Extracell. Vesicles"},{"key":"B152","doi-asserted-by":"publisher","first-page":"473","DOI":"10.3390\/cancers10120473","article-title":"Key role of the Cd56(low)Cd16(low) natural killer cell subset in the recognition and killing of multiple myeloma cells","volume":"10","author":"Vulpis","year":"2018","journal-title":"Cancers (Basel)"},{"key":"B153","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.canlet.2019.11.033","article-title":"Car-Nk for tumor immunotherapy: clinical transformation and future prospects","volume":"472","author":"Wang","year":"","journal-title":"Cancer Lett."},{"key":"B154","doi-asserted-by":"publisher","first-page":"470","DOI":"10.3324\/haematol.13783","article-title":"Proteasome inhibition induces apoptosis in primary human natural killer cells and suppresses Nkp46-mediated cytotoxicity","volume":"94","author":"Wang","year":"2009","journal-title":"Haematologica"},{"key":"B155","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1097\/cji.0000000000000320","article-title":"Bcma-targeting bispecific antibody that simultaneously stimulates Nkg2d-enhanced efficacy against multiple myeloma","volume":"43","author":"Wang","year":"","journal-title":"J. Immunother."},{"key":"B156","doi-asserted-by":"publisher","first-page":"4006","DOI":"10.1158\/1078-0432.Ccr-17-3117","article-title":"Fratricide of Nk cells in daratumumab therapy for multiple myeloma overcome by ex vivo-Expanded autologous Nk cells","volume":"24","author":"Wang","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"B157","doi-asserted-by":"publisher","first-page":"3182","DOI":"10.1182\/blood-2019-128749","article-title":"Ctx-8573, an innate-cell engager targeting bcma, is a highly potent multispecific antibody for the treatment of multiple myeloma","volume":"134","author":"Watkins-Yoon","year":"2019","journal-title":"Blood"},{"key":"B158","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7534\/j.issn.1009-2137.2018.03.027","article-title":"Application of chimeric antigen receptor-modified Nk cells in multiple myeloma","volume":"26","author":"Wei","year":"2018","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"B159","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1124\/jpet.115.225656","article-title":"The pharmacological and physiological role of multidrug-resistant protein 4","volume":"354","author":"Wen","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B160","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1016\/j.stem.2021.08.013","article-title":"Harnessing features of adaptive Nk cells to generate ipsc-derived Nk cells for enhanced immunotherapy","volume":"28","author":"Woan","year":"2021","journal-title":"Cell Stem Cell"},{"key":"B161","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1593\/neo.121236","article-title":"Valproic acid upregulates Nkg2d ligand expression through an erk-dependent mechanism and potentially enhances nk cell-mediated lysis of myeloma","volume":"14","author":"Wu","year":"2012","journal-title":"Neoplasia"},{"key":"B162","doi-asserted-by":"publisher","first-page":"9543","DOI":"10.1073\/pnas.1819745116","article-title":"Exploratory trial of a biepitopic car T-targeting B cell maturation antigen in relapsed\/refractory multiple myeloma","volume":"116","author":"Xu","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B163","doi-asserted-by":"publisher","first-page":"26982","DOI":"10.18632\/oncotarget.4831","article-title":"Carfilzomib enhances natural killer cell-mediated lysis of myeloma linked with decreasing expression of hla class I","volume":"6","author":"Yang","year":"2015","journal-title":"Oncotarget"},{"key":"B164","doi-asserted-by":"publisher","first-page":"5641","DOI":"10.1182\/bloodadvances.2021005883","article-title":"Evaluation of allogeneic and autologous membrane-bound il-21-expanded Nk cells for chronic lymphocytic leukemia therapy","volume":"6","author":"Yano","year":"2022","journal-title":"Blood Adv."},{"key":"B165","doi-asserted-by":"publisher","first-page":"1101495","DOI":"10.3389\/fimmu.2023.1101495","article-title":"Car-T cell therapy in multiple myeloma: current limitations and potential strategies","volume":"14","author":"Zhang","year":"2023","journal-title":"Front. Immunol."},{"key":"B166","doi-asserted-by":"publisher","first-page":"205873921878896","DOI":"10.1177\/2058739218788968","article-title":"The research significance of concomitant use of car-Cd138-nk and car-Cd19-Nk to target multiple myelomas","volume":"16","author":"Zhao","year":"2018","journal-title":"Eur. J. Inflamm."},{"key":"B167","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41408-019-0173-0","article-title":"Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of Stat3 or targeting of Irf4","volume":"9","author":"Zhu","year":"2019","journal-title":"Blood Cancer J."},{"key":"B168","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1158\/2643-3230.BCD-21-0059","article-title":"Bortezomib induces immunogenic cell death in multiple myeloma","volume":"2","author":"Zitvogel","year":"2021","journal-title":"Blood Cancer Discov."}],"container-title":["Frontiers in Cell and Developmental Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2024.1359084\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T04:46:33Z","timestamp":1707713193000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2024.1359084\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,12]]},"references-count":166,"alternative-id":["10.3389\/fcell.2024.1359084"],"URL":"https:\/\/doi.org\/10.3389\/fcell.2024.1359084","relation":{},"ISSN":["2296-634X"],"issn-type":[{"value":"2296-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,12]]},"article-number":"1359084"}}